Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph Mikhael

Showing results (31-40 of 104) with videos related to

Pageof 11
Sort By:
Cancer|June 1, 2012
Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphomaRobert I Griffiths, Michelle L Gleeson, Joseph Mikhael, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 20, 2009
Age 40 years and under does not confer superior prognosis in patients with multiple myeloma undergoing upfront autologous stem cell transmplantParneet K Cheema, Sahar Zadeh, Vishal Kukreti, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|March 16, 2016
Development and Evaluation of a Hematology-Oriented Clinical Research Training Program in Latin AmericaLillian Sung, Eduardo Rego, Eloisa Riva, et al.
Journal of General Internal Medicine|January 12, 2011
Why do patients agree to a "Do not resuscitate" or "Full code" order? Perspectives of medical inpatientsJames Downar, Tracy Luk, Robert W Sibbald, et al.
Medical Care|January 14, 2016
Estimating the Population Benefits and Costs of Rituximab Therapy in the United States from 1998 to 2013 Using Real-World DataMark D Danese, Carolina M Reyes, Michelle L Gleeson, et al.
Frontiers in Oncology|October 2, 2025
A discrete choice experiment analysis to understand patient preferences for multiple myeloma treatmentsBeth Faiman, Hoa H Le, Julie Laurent, et al.
Future Oncology (London, England)|December 14, 2019
Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study designPhilippe Moreau, Meletios A Dimopoulos, Kwee Yong, et al.
Blood|December 31, 2010
An observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic leukemiaMark D Danese, Robert I Griffiths, Michelle Gleeson, et al.
Plos One|September 10, 2021
Supporting newly graduated medical doctors in managing COVID-19: An evaluation of a Massive Open Online Course in a limited-resource settingArdi Findyartini, Nadia Greviana, Chaina Hanum, et al.
American Journal of Hematology|September 16, 2010
IgM multiple myeloma: disease definition, prognosis, and differentiation from Waldenstrom's macroglobulinemiaSteven R Schuster, Sundararajan Vincent Rajkumar, Angela Dispenzieri, et al.
Pageof 11

Showing results (31-40 of 104) with videos related to

Sort By:
Pageof 11
Cancer|June 1, 2012
Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphomaRobert I Griffiths, Michelle L Gleeson, Joseph Mikhael, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 20, 2009
Age 40 years and under does not confer superior prognosis in patients with multiple myeloma undergoing upfront autologous stem cell transmplantParneet K Cheema, Sahar Zadeh, Vishal Kukreti, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|March 16, 2016
Development and Evaluation of a Hematology-Oriented Clinical Research Training Program in Latin AmericaLillian Sung, Eduardo Rego, Eloisa Riva, et al.
Journal of General Internal Medicine|January 12, 2011
Why do patients agree to a "Do not resuscitate" or "Full code" order? Perspectives of medical inpatientsJames Downar, Tracy Luk, Robert W Sibbald, et al.
Medical Care|January 14, 2016
Estimating the Population Benefits and Costs of Rituximab Therapy in the United States from 1998 to 2013 Using Real-World DataMark D Danese, Carolina M Reyes, Michelle L Gleeson, et al.
Frontiers in Oncology|October 2, 2025
A discrete choice experiment analysis to understand patient preferences for multiple myeloma treatmentsBeth Faiman, Hoa H Le, Julie Laurent, et al.
Future Oncology (London, England)|December 14, 2019
Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study designPhilippe Moreau, Meletios A Dimopoulos, Kwee Yong, et al.
Blood|December 31, 2010
An observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic leukemiaMark D Danese, Robert I Griffiths, Michelle Gleeson, et al.
Plos One|September 10, 2021
Supporting newly graduated medical doctors in managing COVID-19: An evaluation of a Massive Open Online Course in a limited-resource settingArdi Findyartini, Nadia Greviana, Chaina Hanum, et al.
American Journal of Hematology|September 16, 2010
IgM multiple myeloma: disease definition, prognosis, and differentiation from Waldenstrom's macroglobulinemiaSteven R Schuster, Sundararajan Vincent Rajkumar, Angela Dispenzieri, et al.
Pageof 11